CaPre omega-3 phospholipids: Phase II amended

On Dec. 17, 2012, Acasti said it amended an open-label, dose-escalation, Canadian Phase II trial of 0.5, 1 and 2 g CaPre daily for 8 weeks to include 4 g CaPre daily following FDA's recommendation. Th...